INTRODUCTION {#s1}
============

Previously, abdominoperineal resection (APR) has been recognized as the preferred surgical method for patients with very low-lying rectal tumors \[[@R1]\]. Despite the fact that this procedure will successfully resect the tumor, it fails to preserve the anal sphincter resulting in the impairment of the anorectal function. Recently, with the development of comprehensive treatment, preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME) has been the standard treatment pattern for locally advanced rectal cancer (LARC), which not only improves the local disease control but also preserves the integrity of the anal sphincter, hence preserving its function \[[@R2], [@R3]\]. Treated with preoperative CRT, most patients achieved a clinically meaningful tumor regression, even reaching a pathologic complete response (pCR) \[[@R4], [@R5]\]. Consequently, downstaging and downsizing the tumor by preoperative CRT allows the surgeon to perform a sphincter preserving resection (SPR) for patients whom APR was initially planned as their next step \[[@R6], [@R7]\]. In fact, patients who received SPR were reported to have higher quality of life than that of those who received APR according to better body image, more sufficient social and sexual functions \[[@R8]--[@R10]\]. Thereby, SPR was well accepted for both patients and surgeons, becoming significantly expanded, or even outweighing APR for treating lower ultra-lower rectal cancer. However, whether sphincter preservation surgery impairs disease control or oncologic survival after CRT in contrast to APR has not been well demonstrated \[[@R11], [@R12]\]. Due to this unclear oncologic survival after SPR, the decision regarding the selection of APR or SPR to treat low-lying LARC after CRT remains controversial.

To achieve a more definite result, we conducted a retrospective cohort study to compare oncologic outcomes of these two different surgical procedures after preoperative CRT in low-lying LARC patients who were initially predicted to undergo APR, done without CRT.

RESULTS {#s2}
=======

Patient\'s characteristics {#s2_1}
--------------------------

Out of 251 eligible patients that were included and received preoperative CRT, 122 patients (48.6%) underwent SPR while 129 patients (51.4%) had APR. The clinical characteristics of both groups were comparable, including age, gender, tumor size, and tumor staging (Table [1](#T1){ref-type="table"}). However, pretreatment tumor location in SPR group was higher with mean of inferior tumor margin distance from the anal verge (DAV) of 5.0 cm, compared to only 3.3 cm in the APR group (*P*=0.001). Treatment parameters including preoperative and postoperative chemotherapy, dose of radiotherapy and the interval from the completion of CRT to surgery were also comparable between the two groups. The defunctioning stoma rate was 8.2% (10/122) in SPR group. Pathological details results are also shown in Table [1](#T1){ref-type="table"}. As shown, patients in SPR group showed a better pathological downstaging after preoperative CRT, achieving significantly higher pCR rate compared to the APR group (32.8% vs 17.8%, *P*=0. 007). Besides, more regional lymph nodes were found in the rectal specimen of SPR group patients than those of the APR group (7 vs 5, *P* =0.030). All patients in the SPR group achieved negative distal resection margin (DRM) with the median length of 2.5 cm (range, 0.5 cm-5 cm).

###### Clinical and pathological characteristics of patients with low-lying locally advanced rectal cancer

  Variables                                                       SPR group       APR group   *P* value
  --------------------------------------------------------------- --------------- ----------- -----------
  Gender                                                                                      0.074
   Male                                                           76(62.3)        94(72.9)    
   Female                                                         41(33.7)        35(27.1)    
  Median age, years (range)                                       57.5(15-78)     54(26-80)   0.056
  Mean DAV, cm (SD)                                               5.0±0.9         3.3±1.5     \<0.001
  Mean size of tumor, cm (SD)                                     3.8±1.3         4.5±1.8     0.740
  cT stage                                                                                    0.231
   3                                                              79(64.8)        74(57.4)    
   4                                                              43(35.2)        55(42.6)    
  cTNM stage                                                                                  0.115
   II                                                             42(34.4)        57(44.2)    
   III                                                            80(65.6)        72(55.8)    
  Preoperative chemotherapy regimen                                                           0.057
   XELOX                                                          104(85.2)       97(75.2)    
   FOLFOX                                                         12(9.8)         26(20.2)    
   Capecitabine                                                   6(4.9)          6(4.7)      
   Dose of radiotherapy, Gy (range)                               46(30-50)       46(30-70)   0.121
  Interval from the completion of CRT to surgery, weeks (range)   6.9(2.9-12.1)   6.7(1-24)   0.104
  Mean size of tumor after CRT, cm (SD)                           3.0±1.7         3.2±1.6     0.200
  Tumor differentiation                                                                       0.227
   Well and moderate                                              96(78.7)        93(72.1)    
   Poor                                                           26(21.3)        36(27.9)    
  Median number of lymph nodes examined (range)                   7(0-27)         5(0-37)     0.030
  Median number of positive lymph nodes (range)                   0(0-12)         0(0-8)      0.840
  ypT stage                                                                                   0.010
   0-2                                                            71(58.2)        54(41.9)    
   3-4                                                            51(41.8)        75(58.1)    
  ypN stage                                                                                   0.840
   0                                                              94(77.0)        98(76.0)    
   1-2                                                            28(23.0)        31(24.0)    
  ypTNM stage                                                                                 0.039
   0                                                              40(32.8)        23(17.8)    
   I                                                              23(19.0)        27(20.9)    
   II                                                             31(25.4)        48(37.2)    
   III                                                            28(23.0)        31(24.0)    
  Achievement of pCR                                                                          0.007
   Yes                                                            40(32.8)        23(17.8)    
   No                                                             82(67.2)        106(82.2)   
  Postoperative chemotherapy regimen                                                          0.153
   None                                                           23(19.9)        21(16.3)    
   Capecitabine                                                   6(4.9)          15(11.6)    
   XELOX or FOLFOX                                                93(76.2)        93(72.1)    
  Median postoperative chemotherapy duration, weeks (range)       12(2-18)        12(2-18)    0.665

Abbreviations: APR: abdominoperineal resection, SPR: sphincterpreserving resection, DAV: inferior tumor margin distance from the anal verge, SD: standard deviation, cTNM stage: clinical tumor-node-metastasis classification, cT stage: clinical tumor stage, ypT stage: pathologic tumor stage after chemoradiotherapy, ypN stage: pathologic node stage after chemoradiotherapy, ypTNM stage: pathologic tumor-node-metastasis classification after chemoradiotherapy, pCR: pathologic complete response, CRT: chemoradiotherapy

Postoperative complications {#s2_2}
---------------------------

The morbidity of postoperative complications was 24.6% in SPR group, which was not significantly different from that of the APR group (20.9%, *P*=0.445). Postoperatively, dysphoria was the most observed complication (10.7%) in the SPR group. Other complications included anastomotic leakage (4.9%), anastomotic stricture (4.1%), intestinal obstruction (2.5%), postoperative pelvic bleeding (1.6%), and pelvic abscess (0.8%). On the other hand, poor wound healing was the most common complication in the APR group, observed in 16 (12.4%) patients. Other complications observed were intestinal obstruction 5 (3.9%), postoperative pelvic bleeding 2 (1.6%) and pelvic abscess found in only 1(0.8%) patient.

Recurrence and survival {#s2_3}
-----------------------

The median duration of the follow-up was 48.6 months (range: 4--130 months). As shown in Table [2](#T2){ref-type="table"}, local recurrence was observed in 2 patients (1.6%) of the SPR group and 5 (3.9%) of the APR group (*P*=0.297), while distant recurrence was documented in 18 patients (14.8%) of SPR group and 32 (24.8%) of APR group (*P*=0.046). Lung was the most common site of metastasis in both groups. The cumulative incidence of local recurrence within 3 years was 1.9 % in SPR group, which was not significantly different from that of the APR group (5.3%, *P*= 0.229, Figure [1A](#F1){ref-type="fig"}). However, cumulative incidence of distant recurrence within 3 years in APR group was almost two fold higher than that of the SPR group (23.7% vs 12.0%, *P*=0.026, Figure [1B](#F1){ref-type="fig"}). The estimated 3-year DFS was 86.4% for the SPR group, significantly higher than that of APR group (73.6%, *P*=0.023, Figure [2A](#F2){ref-type="fig"}), while the estimated 3-year OS rate was 89.6% for SPR group and 81.8% for APR group respectively (*P*=0.316, Figure [2B](#F2){ref-type="fig"}). Moreover, for SPR group patients, no significant difference in the 3-year DFS was found based on DRM (*P*=0.399, Table [3](#T3){ref-type="table"}). Univariate analysis for the factors affecting the 3-year DFS revealed that surgical procedure, pathologic T and N stages were the significant prognostic factors (Table [3](#T3){ref-type="table"}). These factors were further assessed by Cox proportional hazards model and surgical procedure was not found to be an independent prognostic factor (Table [4](#T4){ref-type="table"}).
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###### Patterns of local and distant recurrence in the low-lying locally advanced rectal cancer patients after preoperative chemoradiotherapy and radical resection

  Categories           Localization   SPR group   APR group   *P* value
  -------------------- -------------- ----------- ----------- -----------
  Local recurrence                                            
  Peripheral type                     1(0.8)      4(3.1)      
  Central type                        1(0.8)      1(0.8)      
                       Total          2(1.6)      5(3.9)      0.297
  Distant recurrence                                          
  Multiple organ                      3(2.4)      4(3.2)      
  Single organ         Lung           8(6.6)      11(8.5)     
                       Liver          5(4.1)      9(7.0)      
                       Bone           1(0.8)      2(1.6)      
                       Peritoneum     1(0.8)      6(4.7)      
                       Total          18(14.8)    32 (24.8)   0.046

Abbreviations: APR: abdominoperineal resection, SPR: sphincter preserving resection

###### Univariate analysis of prognostic factors for 3-year disease free survival

  Clinical factors                               Cases   3-year DFS rate (%)   *P* value
  ---------------------------------------------- ------- --------------------- -----------
  Gender                                                                       0.371
   Male                                          170     80.2                  
   Female                                        81      79                    
  Age, year                                                                    0.667
   ≤60                                           84      78.6                  
   \>60                                          167     80.4                  
  DAV (cm)                                                                     0.075
   ≤3                                            75      71.1                  
   \>3                                           176     83.4                  
  Preoperative chemoradiotherapy regimen                                       0.086
   XELOX                                         201     81.9                  
   FOLFOX                                        38      80.7                  
   Capecitabine                                  12      41.7                  
  Dose of radiotherapy (Gy)                                                    0.783
   \<50                                          188     79.9                  
   ≥50                                           63      80.0                  
  postoperative chemotherapy duration (weeks)                                  0.559
   \<12                                          89      78.8                  
   ≥12                                           162     80.4                  
  Surgical procedure                                                           0.023
   SPR                                           122     86.4                  
   APR                                           129     73.6                  
  Tumor differentiation                                                        0.962
   Well and moderate                             189     79.4                  
   Poor                                          62      81.2                  
  ypT stage                                                                    \<0.001
   0-2                                           125     89                    
   3-4                                           126     70.8                  
  ypN stage                                                                    \<0.001
   0                                             192     86.7                  
   1-2                                           59      57                    
  DRM (cm)[^a^](#tfn_001){ref-type="table-fn"}                                 0.399
   0-1                                           12      91.7                  
   1-2                                           47      91.1                  
   2-3                                           38      86.3                  
   3-4                                           14      71.4                  
   4-5                                           11      80                    

Abbreviations: DFS: Disease Free Survival, APR: abdominoperineal resection, SPR: sphincter preserving resection, DAV: inferior tumor margin distance from the anal verge, ypT stage: pathologic tumor stage after chemoradiotherapy, ypN stage: pathologic node stage after chemoradiotherapy, DRM: distal resection margin.

Patients only undergoing SPR

###### Multivariate analysis of prognostic predictors for 3-year disease free survival

  Variables            Cases   HR          95% CI for HR   *P* value
  -------------------- ------- ----------- --------------- -----------
  ypT stage                                                0.020
   0-2                 125     Reference   \-              
   3-4                 126     2.090       1.123-3.889     
  ypN stage                                                \<0.001
   0                   192     Reference   \-              
   1-2                 59      2.992       1.737-5.153     
  Surgical procedure                       0.075           
   SPR                 122     Reference   \-              
   APR                 129     1.650       0.951-2.863     

Abbreviations: HR:Hazard ratio, APR: abdominoperineal resection, SPR: sphincter preserving resection, ypT stage: pathologic tumor stage after chemoradiotherapy, ypN stage: pathologic node stage after chemoradiotherapy

DISCUSSION {#s3}
==========

Although APR is still a main procedure in the management of low-lying rectal cancer, the application of preoperative CRT combined with SPR has been becoming more widespread used \[[@R13], [@R14]\]. According to the final assessment of 251 patients with low-lying LARC, SPR was performed in 48.6% patients with significantly better 3-year DFS rate (*P*=0.023) and lower incidence of distant recurrence (*P*=0.026) compared to APR.

It was noted that response to preoperative CRT had an important role in increasing the possibility of preserving the anal sphincter in surgery \[[@R15], [@R16]\]. Preoperative CRT can help shrink the tumor to provide more operating space for surgical resection, which might be otherwise hard to perform \[[@R7]\]. In our study, we found that these patients who achieved pCR were more likely to undergo SPR than those who didn\'t (63.5% vs 43.6%, *P*=0.007). Added to that, due to tumor regression after preoperative CRT, DRM might be getting longer allowing enough distal rectal length for anastomosis. One concern of performing SPR for the low-lying rectal cancer is to ensure an adequate surgical distal resection margin to prevent local recurrence \[[@R17]\]. In general, DRM of 2 cm has been recommend for patients who have not received CRT \[[@R18]\], while it was demonstrated that after CRT, a DRM of at least 1 cm did not jeopardize oncological safety \[[@R19], [@R20]\]. Poricolo et al set 1 cm as the length of DRM for rectal cancer resection after CRT and observed no local recurrence within 48.8 months follow-up \[[@R19]\]. Kwak et al even suggested a distal margin of at least 5 mm with negative resection margin guaranteed oncological safety after CRT \[[@R20]\]. Our data also showed that once negative resection margin was achieved, 3-year DFS seemed not to be correlated with DRM after preoperative CRT (*P*=0.399). Therefore, preoperative CRT can provide a shorter resection margin without increasing the risk of local and distant recurrence, which makes colorectal anastomosis easier.

Although the oncologic outcome was a highlight of selecting the feasible surgical procedure for low-lying LARC, there were limited studies comparing oncologic outcomes between SPR and APR following CRT \[[@R12], [@R21], [@R22]\]. Huh et al reported that there were no significant difference in the overall recurrence rate (20.9% vs 20.5%, *P* = 0.956) and 5-year OS(70.8% vs 62.9%, *P*= 0.189) \[[@R12]\]. On the contrary, Weiser et al noted that APR compromise local control and recurrence-free survival. They showed that 5-years recurrence-free survival for the stapled anastomosis, intersphincteric resection, and APR groups were 85%, 83%, and 47% respectively (P\< 0.001) \[[@R21]\]. Kim et al also reported that patients who underwent APR had higher 5-year local recurrence (22.0% vs. 11.5%, *P* = 0.028) and lower 5-year cancer-specific survival rate (52.9% vs. 71.1%, *P* = 0.030) than those who underwent SPR \[[@R22]\]. Similarly, our results showed that even though incidence of local recurrence was comparable between the two groups (1.9% vs 5.3%, *P* = 0.229), the distant recurrence in APR was significantly higher than the SPR group (23.7% vs 12.0%, P=0.026). In addition, patients in APR group exhibited worse 3-year DFS than those in the SPR group (73.6% vs 86.4%, *P*=0.023). To explain the common results that APR delivered a worse recurrence control and worse oncologic outcome, the postoperative pathologic factors of patients should be taken into consideration. Sphincter preservation tends to be considered more in the patients with a significant pathologic response to preoperative CRT. On the other hand, older patients, patients with poor tumor differentiation and less response tumor were more likely to undergo APR. These prognostic high-risk factors were also associated with higher recurrence and worse survival \[[@R21], [@R23]\]. In this current study, pathologic T and N stage were the independent predictors for 3-year DFS (*P* =0.020 and *P*\<0.001). Since achievement of pCR after preoperative CRT is associated with greatly improved long-term outcome in LARC \[[@R24], [@R25]\], a higher pCR rate in SPR group might account for the better oncologic outcome in comparison with the APR group (32.8% vs 17.8%, *P*=0.007).

Several potential limitations should be acknowledged. First of all, selective bias of dividing the patients into different groups was unavoidable due to the retrospective nature of this study. As we have mentioned above, patients with lower tumor location (DAV \< 3cm) were only selected for APR, which resulted in the bias of tumor location in these two groups. However, with careful planning and a multidisciplinary approach, rectal cancer height did not influence the oncological outcome \[[@R26], [@R27]\]. Similarly, we found tumor location had no significant impact on DFS in the current study, as showed in Table [3](#T3){ref-type="table"}. Furthermore, the surgeon specialization and technical expertise have been considered as important factors of the surgical procedure decision for low-lying LARC \[[@R28]\]. Since quality of life was another important long-term outcome of rectal cancer after surgery, we also failed to evaluate it in our study. This limitation may have led to underestimate the quality of life after CRT followed by SPR or APR influencing the oncologic survival. Moreover, we also realized that the insufficient follow-up time was unable to measure the 5-year OS for patients. Despite of those limitations mentioned above, our study indeed provided the critical information for the optimal strategy for treating low-lying LARC patients.

In conclusion, preoperative CRT provides an opportunity for those who initially deserve APR to undergo SPR without compromising oncologic survival. SPR can be a practicable alternative for the treatment of low-lying LARC patients who response well to preoperative CRT, to approach the concurrent requirement of adequate oncological control along with sphincter functional preservation.

PATIENTS AND METHODS {#s4}
====================

Patient selection {#s4_1}
-----------------

This retrospective cohort study enrolled a total of 251 consecutive LARC patients who underwent preoperative CRT followed by radical resection at Sun Yat-sen University Cancer center between March 2003 and November 2012. All patients met the following inclusion criteria: (1) Histological diagnosed rectal adenocarcinoma; (2) Inferior tumor margin within 6 cm from the anal verge before CRT; (3) T3-4 or N+ disease of pretreatment; (4) Radical resection with either SPR or APR; (5) No metastatic disease before and during preoperative treatment; (6) No other active malignancy (excluding skin basal cell carcinoma). Pretreatment staging was performed by endorectal ultrasound (EUS), chest and abdominopelvic computed tomography scanning (CT), and/or pelvic magnetic resonance imaging (MRI). Tumor location was confirmed both by colonoscopy and digital rectal examination. The eligible patients were assigned into two different groups according to the surgical procedures they had received, either SPR group or APR group. Overall data including the general clinical and tumor characteristics, treatment parameters, postoperative complications were recorded in detail. The study was done in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. A Waiver of Informed Consent was requested and the study approval was obtained from independent ethics committees at Sun Yat-Sen University Cancer Center.

Treatment {#s4_2}
---------

Radiation therapy was administered using three dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). All patients were scheduled a total irradiation dose of 46.0--50.40 Gy to the pelvic area, delivered in fractions of 1.8 Gy or 2.0 Gy daily on five consecutive days per week during 5-6 weeks. The clinical target volume included macroscopic tumor, entire mesorectum, and pararectal lymph nodes, together with internal iliac, anal sphincter complex, promontory and pre-sacral lymph nodes up to the level of the fifth lumbar vertebra. XELOX regimen (oxaliplatin was administered intravenously 130 mg/m^2^ on days 1 and capecitabine was administered orally 1,000 mg/m^2^ twice daily on days 1-14 for 3 week-cycle), FOLFOX regimen (oxaliplatin 85 mg/m^2^ and leucovorin 400 mg/m^2^ was administered intravenously over 2 hours on the first day, 5-fluorouracil was injected intravenously 400 mg/m^2^ on the first day and then administered 2400 mg/m^2^ by continuous intravenous infusion for 46 hours for 2 week-cycle) or oral capecitabine (oral capecitabine 825 mg/m^2^ was given twice daily during radiotherapy without weekend breaks) was alternatively delivered concurrently with neoadjuvant radiotherapy.

Radical surgery was planned to be performed between 6 to 8 weeks after the completion of preoperative radiotherapy. All surgical operations were performed by experienced surgeons. The decision of surgical procedure was based on tumor location, pelvic space and the extent of anal sphincter invasion, while TME was performed whenever possible. For the unsatisfactory colorectal anastomosis, a diverting loop ileostomy was required.

Pathological assessment of the resected specimens was confirmed according to tumor-node-metastasis classification (TNM) by two independent pathologists. Pathologic complete response (pCR) was defined as follow: the absence of viable tumor cells with only fibrotic masses or acellular mucin pools present in area of primary tumor and lymph nodes \[[@R29]\]. Distal margins were considered positive once microscopic tumor was identified within 1 mm of resection \[[@R30]\]. Oxaliplatin based adjuvant chemotherapy was recommended.

Endpoints and follow-up {#s4_3}
-----------------------

The primary endpoint was 3-year DFS, while secondary endpoints included OS, cumulative incidence of recurrences and postoperative complications. All patients were evaluated through subsequent visits every 3 months for 2 years and then semiannually until 5 years postoperatively. At each follow-up visit, evaluation included physical examination, serum carcinoembryonic antigen (CEA) level, chest X-ray and abdominal ultrasound. Chest CT, abdominal/pelvic MRI, and colonoscopy were performed annually. Recurrence was confirmed by histological examination whenever possible or after assessment by a multidisciplinary treatment group. Recurrence in pelvis was defined as local recurrence and recurrence outside the pelvis was considered as distant metastasis.

Statistical analysis {#s4_4}
--------------------

All data were analyzed using Statistical Package for the Social Sciences (SPSS, version 17.0, Chicago, IL). Quantitative variables were presented as mean (standard deviation) or median (range) and then compared based on the Student t-test or Mann-Whitney U test which ever appropriate. Qualitative variables were given as percentage and compared by applying Chi square test or Fisher\'s exact, as appropriate. Kaplan-Meier methodology was applied to calculate DFS, OS and cumulative incidences of recurrence by outlining the survival curve. Log-rank test was applied to distinguish the difference between groups. Univariate analysis of prognostic factors was also evaluated by log-rank test. Variables proved statistical significance in the univariate survival analysis were further assessed by Cox proportional hazards model, which was generated with forward stepwise selection of variables. All tests were two-tailed, in which P value \< 0.05 was considered to be statistically significant.

We would like to thank all colleagues of Department of Colorectal Surgery and Radiation Oncology in Sun Yat-sen University Cancer Center, who have involved with performing the treatment for current study.

**CONFLICTS OF INTEREST**

All authors declared that there is no conflicts of interest.

**FUNDING**

This work was supported by no funding.
